| 0.35 -0.01 (-2.78%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.48 | 1-year : | 0.58 |
| Resists | First : | 0.41 | Second : | 0.5 |
| Pivot price | 0.34  |
|||
| Supports | First : | 0.28 | Second : | 0.23 |
| MAs | MA(5) : | 0.35 |
MA(20) : | 0.33 |
| MA(100) : | 0.61 |
MA(250) : | 0.98 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 66.9 |
D(3) : | 71.4 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 2.23 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CODX ] has closed below upper band by 42.8%. Bollinger Bands are 62.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.36 - 0.36 | 0.36 - 0.36 |
| Low: | 0.33 - 0.33 | 0.33 - 0.33 |
| Close: | 0.35 - 0.35 | 0.35 - 0.35 |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Wed, 02 Apr 2025
All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy - Nasdaq
Fri, 28 Mar 2025
Co-Diagnostics Inc (CODX) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Thu, 27 Mar 2025
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results - PR Newswire
Thu, 27 Mar 2025
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates - Nasdaq
Thu, 13 Mar 2025
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast - Yahoo Finance
Thu, 13 Mar 2025
Co-Diagnostics Sets Date for Crucial Year-End 2024 Financial Results - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 3.136e+007 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 233 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.87e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 973.9 % |
| Return on Equity (ttm) | -31.5 % |
| Qtrly Rev. Growth | 3.92e+006 % |
| Gross Profit (p.s.) | -79.18 |
| Sales Per Share | -44.34 |
| EBITDA (p.s.) | 2.41322e+006 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.25 |
| Dividend | 0 |
| Forward Dividend | 202410 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|